Premium
Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective
Author(s) -
Iannelli Mauro,
Caminiti Lucia,
Vaccaro Mario,
Marafioti Ilenia,
Spinuzza Antonietta,
Panasiti Ilenia,
Barbalace Andrea,
Crisafulli Giuseppe,
Pajno Giovanni B.
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13519
Subject(s) - omalizumab , dupilumab , medicine , atopic dermatitis , dermatology , asthma , immunoglobulin e , refractory (planetary science) , monoclonal , monoclonal antibody , immunology , antibody , physics , astrobiology
Omalizumab is a monoclonal antibody, targeting Fc receptor of IgE, approved for the treatment of allergic asthma and chronic spontaneous urticaria. Its utility in atopic dermatitis appears controversial from data in literature since the molecule is well tolerated but it seems less effective than other medications used in adult patients (eg, Dupilumab). At present, the use of Dupilumab is not approved in pediatric patients therefore there are no second level treatments available in this age group. Here we report two clinical cases of patients (15 and 16 years old) suffering from both atopic dermatitis and asthma, treated with Omalizumab. Our experience suggests that atopic eczema of young patients with allergic comorbidities can benefit from asthma treatment with Omalizumab observing improvement on both conditions.